3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Interventions
Rituximab
45
Cyclophosphamide
38
ibrutinib
22
fludarabine
22
acalabrutinib
21
venetoclax
20
zanubrutinib
17
Lenalidomide
17
Bendamustine Hydrochloride
17
obinutuzumab
16
fludarabine phosphate
14
Magnetic Resonance Spectroscopy
14
Cytarabine
14
Specimen Handling
13
CT-P10
13
pirtobrutinib
12
Biopsy
12
glofitamab
10
Etoposide
10
Whole-Body Irradiation
9
Vincristine
7
Peripheral Blood Stem Cell Transplantation
7
Mycophenolic Acid
7
Melphalan
7
Doxorubicin
7
brexucabtagene autoleucel
6
Cyclosporine
6
orelabrutinib
5
Methotrexate
5
Immunotherapy, Adoptive
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Mantle-Cell
×
CLR1404
×
1 year
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled